- Home
- AFRI vs RZLT Comparison
AFRI vs RZLT Comparison
Compare AFRI & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AFRI
- RZLT
- Stock Information
- Founded
- AFRI 1943
- RZLT 2010
- Country
- AFRI Gibraltar
- RZLT United States
- Employees
- AFRI N/A
- RZLT N/A
- Industry
- AFRI Packaged Foods
- RZLT Biotechnology: Pharmaceutical Preparations
- Sector
- AFRI Consumer Staples
- RZLT Health Care
- Exchange
- AFRI Nasdaq
- RZLT Nasdaq
- Market Cap
- AFRI 278.3M
- RZLT 303.1M
- IPO Year
- AFRI N/A
- RZLT N/A
- Fundamental
- Price
- AFRI $10.35
- RZLT $4.91
- Analyst Decision
- AFRI
- RZLT Strong Buy
- Analyst Count
- AFRI 0
- RZLT 8
- Target Price
- AFRI N/A
- RZLT $11.63
- AVG Volume (30 Days)
- AFRI 7.6K
- RZLT 383.1K
- Earning Date
- AFRI 12-23-2024
- RZLT 11-07-2024
- Dividend Yield
- AFRI N/A
- RZLT N/A
- EPS Growth
- AFRI N/A
- RZLT N/A
- EPS
- AFRI N/A
- RZLT N/A
- Revenue
- AFRI $305,476,000.00
- RZLT N/A
- Revenue This Year
- AFRI N/A
- RZLT N/A
- Revenue Next Year
- AFRI N/A
- RZLT N/A
- P/E Ratio
- AFRI N/A
- RZLT N/A
- Revenue Growth
- AFRI 5.42
- RZLT N/A
- 52 Week Low
- AFRI $9.63
- RZLT $0.72
- 52 Week High
- AFRI $12.00
- RZLT $6.19
- Technical
- Relative Strength Index (RSI)
- AFRI 47.91
- RZLT 41.20
- Support Level
- AFRI $10.02
- RZLT $4.66
- Resistance Level
- AFRI $10.55
- RZLT $5.14
- Average True Range (ATR)
- AFRI 0.30
- RZLT 0.42
- MACD
- AFRI 0.01
- RZLT -0.11
- Stochastic Oscillator
- AFRI 28.15
- RZLT 16.38
About AFRI Forafric Global PLC
Forafric Global PLC is engaged in production and sale of a variety of wheat flours, Semolina and Pasta and Couscous in Morocco and in more than 45 countries. The two main brands in Morocco are MAYMOUNA and TRIA. The company derives majority of its revenue from Soft wheat.
About RZLT Rezolute Inc. (NV)
Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402.